AI-designed vaccine shows promise in human trials
人工智慧設計的疫苗在人體試驗中展現潛力
更新於: 2026年6月6日 上午07:30
In a groundbreaking development for medical science, researchers have successfully tested the first vaccine component entirely designed by artificial intelligence.
在醫學界的一項突破性發展中，研究人員成功測試了首個完全由人工智慧設計的疫苗成分。
Led by scientists at the University of Cambridge and DIOSynVax, this innovative study focuses on a 'future-proof' vaccine called pEVAC-PS.
這項創新研究由劍橋大學與 DIOSynVax 的科學家主導，重點在於一種稱為 pEVAC-PS 的「未來防禦」型疫苗。
By analyzing the genetic codes of all known sarbecoviruses, the AI identified shared features across the entire virus family.
透過分析所有已知沙貝病毒(Sarbecoviruses)的遺傳密碼，AI 辨識出了整個病毒家族共有的特徵。
This allows the vaccine to prime the immune system to recognize not only current variants but also future mutations that haven't emerged yet.
這使得疫苗能夠引導免疫系統，不僅能識別當前的變異株，還能應對尚未出現的未來變異。
During a Phase I clinical trial involving 39 volunteers, the DNA vaccine was administered via a needle-free jet, proving safe and well-tolerated.
在涉及 39 名志願者的第一期臨床試驗中，這種 DNA 疫苗透過無針噴射方式施打，證實安全且耐受性良好。
Participants demonstrated promising immune responses against a broad range of coronaviruses.
參與者對多種冠狀病毒展現出顯著的免疫反應。
This shift from reactive to proactive development could change how we handle pandemics.
這種從被動應對轉向主動開發的模式，可能會改變我們應對大流行病的方式。
Following these successful initial results, researchers are planning larger studies to confirm these findings and move closer to a new era of global pandemic preparedness.
繼這些成功的初步結果後，研究人員正計劃進行更大規模的研究，以證實這些發現，並邁向全球大流行病準備的新時代。
